Comparison of skin concentrations following topical versus oral corticosteroid treatment: Reconsidering the treatment of common inflammatory dermatoses

Journal of Drugs in Dermatology

Volumn 8, Issue 12, 2009, Pages 1076-1079

  McClain, Richard W ^a   Yentzer, Brad A ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; HYDROCORTISONE; PREDNISONE; TRIAMCINOLONE ACETONIDE; CORTICOSTEROID;

ARTICLE; CORTICOSTEROID THERAPY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG POTENCY; SKIN DISEASE; SYSTEMIC THERAPY; TISSUE DISTRIBUTION; TOPICAL TREATMENT; COMPARATIVE STUDY; DERMATITIS; HUMAN; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; SKIN;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; DERMATITIS; HUMANS; SKIN;

EID: 74049108180     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ghaffar SA, Clements SE, Griffiths CE. Modern management of psoriasis. Clin Med. 2005;5(6):564-568.
2. Buys LM. Treatment options for atopic dermatitis. Am Fam Physician. 2007;75(4):523-528.
3. Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000;320(7240):963-967.
4. Gottlieb AB. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol. 2005;53(1 Suppl 1):S3-S16.
5. Gold Standard I. Clinical pharmacology: Prednisone. http://www. clinicalpharmacology.com. 2007. Accessed August 22, 2007.
6. Huang X, Tanojo H, Lenn J, et al. A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol. 2005;53(1 Suppl 1):S26-S38.
7. European Medicines Agency (EMEA), European Union. Clinical investigation of corticosteroids intended for use on the skin. http://www.emea europa eu/pdfs/human/ewp/3cc26aen.pdf. 2007;347-357. Accessed August 22, 2007.
8. Pellanda C, Ottiker E, Strub C, et al. Topical bioavailability of triamcinolone acetonide: Effect of dose and application frequency. Arch Dermatol Res. 2006;298(5):221-230.
9. Borsadia S, Ghanem AH, Seta Y, et al. Factors to be considered in the evaluation of bioavailability and bioequivalence of topical formulations. Skin Pharmacol. 1992;5(3):129-145.
10. Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an eight-week psoriasis clinical trial: Commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51(2):212-216.
11. Ferry JJ, Horvath AM, Bekersky I, et al. Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol. 1988;28(1):81-87.
12. Gysler A, Kleuser B, Sippl W et al. Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin. Pharm Res. 1999;16(9):1386-1391.
13. Haigh JM, Kanfer I. Assessment of topical corticosteroid preparations: The human skin blanching assay. Int J Pharma. 1984;19(3):245-262.
14. Krejci-Manwaring J, McCarty MA, Camacho F, et al. Adherence with topical treatment is poor compared with adherence with oral agents: Implications for effective clinical use of topical agents. J Am Acad Dermatol. 2006;54(5 Suppl):S235-S236.
15. Lademann J, Ilgevicius A, Zurbau O, et al. Penetration studies of topically applied substances: Optical determination of the amount of stratum corneum removed by tape stripping. J Biomed Opt. 2006;11(5):054026.
16. Lee Y, Hwang K. Skin thickness of Korean adults. Surg Radiol Anat. 2002;24(3-4):183-189.
17. Majaron B, Verkruysse W, Kelly KM, Nelson JS. Er:YAG laser skin resurfacing using repetitive long-pulse exposure and cryogen spray cooling: II. Theoretical analysis. Lasers Surg Med. 2001;28(2):131-137.
18. Mueller B, Anissimov YG, Roberts MS. Unexpected clobetasol propionate profile in human stratum corneum after topical application in vitro. Pharm Res. 2003;20(11):1835-1837.
19. Nickoloff BJ. Skin innate immune system in psoriasis: Friend or foe? J Clin Invest. 1999;104(9):1161-1164.
20. Rapaport MJ, Lebwohl M. Corticosteroid addiction and withdrawal in the atopic: the red burning skin syndrome. Clin Dermatol. 2003;21(3):201-214.
21. Richards HL, Fortune DG, O'Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol. 1999;41(4):581-583.
22. Schaefer H, Zesch A, Stuttgen G. Penetration, permeation 22. and absorption of triamcinolone acetonide in normal and psoriatic skin. Arch Dermatol Res. 1977;258(3):241-249.
23. Schlagel CA, Sanborn EC. The weights of topical preparations required for total and partial body inunction. J Invest Dermatol. 1964;42:253-256.
24. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol. 2002;46(6):886-891.
25. Uribe M, Schalm SW, Summerskill WH, Go VL. Oral prednisone for chronic active liver disease: Dose responses and bioavailability studies. Gut. 1978;19(12):1131-1135.
26. Wallace SM, Falkenberg HM, Runikis JO, Stewart WD. Skin levels and vasoconstrictor assay of topically applied hydrocortisone. Arch Dermatol. 1979;115(4):440-441.
27. Proksch E, Folster-Holst R, Jensen JM. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci. 2006;43(3):159-169.
28. Jarratt MT, Clark SD, Savin RC, et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaquetype psoriasis. Cutis. 2006;78(5):348-354.
29. Rowlands CG, Danby FW. Histopathology of psoriasis treated with zinc pyrithione. Am J Dermatopathol. 2000;22(3):272-276.
30. Zanolli M. Phototherapy arsenal in the treatment of psoriasis. Dermatol Clin. 2004;22(4):397-406.
31. Meduri NB, Vandergriff T, Rasmussen H, Jacobe H. Phototherapy in the management of atopic dermatitis: A systematic review. Photodermatol Photoimmunol Photomed. 2007;23(4):106-112.
32. Miraglia del Giudice M, Decimo F, Leonardi S, et al. Immune dysregulation in atopic dermatitis. Allergy Asthma Proc. 2006;27(6):451-455.
33. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: Are ointments really more potent? J Drugs Dermatol. 2006;5(6):527-532.